TORONTO, March 7, 2023 /CNW/ - Intellipharmaceutics International Inc. (OTCQB: IPCIF) (TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that the Ontario Securities Commission (the "OSC") has issued a general "failure to file" cease trade order pursuant to National Policy 11-103 – Failure to File Cease Trade Orders in Multiple Jurisdictions (the "CTO") dated March 6, 2023 in respect of the securities of the Company as a result of the Company's inability to file its annual audited financial statements, management's discussion and analysis, Chief Executive Officer and Chief Financial Officer certificates and annual information form for the fiscal year ended November 30, 2022 (collectively, the "Required Filings") due February 28, 2023 (the "Filing Deadline").
Read more at newswire.caProvided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.